hnps-PLA Inhibitor

CAS No. 185298-58-2

hnps-PLA Inhibitor( hnps-PLA Inhibitor | MDK-8582 | MDK 8582 )

Catalog No. M17396 CAS No. 185298-58-2

Hnps-PLA Inhibitor is an inhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 132 In Stock
2MG 70 In Stock
5MG 116 In Stock
10MG 202 In Stock
25MG 341 In Stock
50MG 498 In Stock
100MG 710 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    hnps-PLA Inhibitor
  • Note
    Research use only, not for human use.
  • Brief Description
    Hnps-PLA Inhibitor is an inhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA).
  • Description
    MDK-8582, also known as Hnps-PLA Inhibitor, is an nhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA). The best one inhibited hnps-PLA(2) and LTA(4)H-h with IC(50) values of 9.2 ± 0.5 μM and 2.4 ± 1.4 μM, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    hnps-PLA Inhibitor | MDK-8582 | MDK 8582
  • Pathway
    Angiogenesis
  • Target
    FGFR
  • Recptor
    LTA(4)H-h| hnsPLA2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    185298-58-2
  • Formula Weight
    379.42
  • Molecular Formula
    C21H21N3O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)N)ccc2
  • Chemical Name
    2-(4-(2-Amino-2-oxoethoxy)-1-benzyl-2-ethyl-1H-indol-3-yl)-2-oxoacetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Meng H, Liu Y, Zhai Y, Lai L. Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase. Eur J Med Chem. 2013 Jan;59:160-7
molnova catalog
related products
  • FGFR2-IN-3

    FGFR2-IN-3 is an orally active selective FGFR2 inhibitor.

  • BLU-554

    BLU-554 (Fisogatinib, BLU554) is a novel potent, highly selective and orally bioavailable inhibitor of FGFR4 designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation.

  • SM27

    SM27 is a fibroblast growth factor 2 (FGF2) inhibitor with anti-angiogenic activity and can be used to study tumours.